Compare HOLX & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLX | PEN |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 13.2B |
| IPO Year | 1995 | 2015 |
| Metric | HOLX | PEN |
|---|---|---|
| Price | $75.09 | $335.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 17 |
| Target Price | $77.89 | ★ $357.33 |
| AVG Volume (30 Days) | ★ 2.2M | 566.6K |
| Earning Date | 04-27-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | 0.79 | ★ 4.52 |
| Revenue | ★ $4,100,500,000.00 | $1,403,665,000.00 |
| Revenue This Year | $4.74 | $14.20 |
| Revenue Next Year | $5.03 | $13.60 |
| P/E Ratio | $95.21 | ★ $74.11 |
| Revenue Growth | 1.74 | ★ 17.50 |
| 52 Week Low | $51.90 | $221.26 |
| 52 Week High | $75.75 | $362.41 |
| Indicator | HOLX | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 43.41 |
| Support Level | $74.53 | $302.19 |
| Resistance Level | $75.35 | $344.07 |
| Average True Range (ATR) | 0.21 | 2.39 |
| MACD | -0.05 | -0.93 |
| Stochastic Oscillator | 9.29 | 18.85 |
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.